Omeros (OMER) Q2 2026 Earnings Call Transcript

Omeros reported Yartemlia Q2 gross sales of $32.2M and net sales of $28.5M, up 190% and 188% QoQ respectively, alongside $4.1M in positive operating cash flow. The company also strengthened its balance sheet by repurchasing $30.5M of 2029 convertible notes in July, cutting outstanding principal by 43% (from ~$70.8M to $40.3M) and eliminating $8.6M in future interest payments; it also retired 489k shares at an average $11.70. However, Europe’s EMA CHMP adopted a negative opinion on its Yartemlia marketing authorization for TA-TMA, prompting a re-examination process, which tempers the outlook.

Analysis

The near-term setup is less about a biotech “beat” and more about a reimbursement-to-procurement conversion story. Once payment is standardized, hospital economics stop being an excuse, so the next leg depends on whether transplant centers move from pilot usage to embedded order sets and repeat ordering. That makes the stock’s real swing factor the rate of sequential adoption over the next 1-2 quarters, not the reported quarterly gross sales print.

The main loser is off-label C5 blockade: if centers are already shifting to a cleaner reimbursement path with a differentiated safety profile, the legacy products lose what little procedural inertia they still had. Second-order, the bigger prize is diagnostic expansion: if the disease is screened earlier instead of treated as a late exclusion diagnosis, the addressable patient pool can expand materially without any new label change. That means the commercial upside is not capped by current incidence assumptions; the risk is that adoption stalls before institutional workflows change.

Balance-sheet actions matter because they reduce the equity’s financing overhang and compress the probability of another dilutive capital raise, but they do not eliminate volatility from the remaining convert structure. The key falsifiers are simple: if ordering growth slows after the reimbursement dates, if gross-to-net drifts up meaningfully from the low-teens, or if management cannot show a broader center penetration curve by year-end, the market will treat this as a front-loaded launch rather than a durable franchise. Europe is option value, not the base case; the stock should be judged on U.S. execution alone over the next 6-12 months.

Key Decisions for Investors

• Long OMER common on pullbacks into the Oct. 1 reimbursement catalyst; hold for 1-3 months and underwrite upside only if sequential net sales and center ordering continue to accelerate. Falsify if post-NTAP revenue growth decelerates or gross-to-net moves above ~15%.
• If you want beta control, run a small long OMER / short AZN pair for 1-3 months to isolate TA-TMA share shift versus diversified pharma exposure. This is a relative-value trade, not a structural short on AZN.
• Use OMER Jan-2027 call spreads instead of stock only if you expect a sharp re-rating on Q3/Q4 adoption data; the setup is attractive because the catalyst path is known, but time decay is real if center penetration plateaus.
• Set a watch alert for Q3 ordering frequency and year-end account count rather than headline EPS. A sustained move in repeat orders is the clearest proof that this is becoming a protocolized market.
• Do not short the name into the current catalyst window unless evidence emerges that reimbursement is not translating into utilization; the note repurchase and lower dilution make downside less clean than before.